Poloxamer for cell culture

Poloxamers with specific ethylene oxide and polypropylene oxide ratios offer improved shear protection and reduced foam formation, enhancing cell viability and productivity in cell culture media by minimizing antifoam agent requirements.

JP7824943B2Active Publication Date: 2026-03-05MERCK PATENT GMBH
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023524288
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-10-21
Filing Date
2021-10-20
Publication Date
2026-03-05
Estimated Expiration
2041-10-20

AI Technical Summary

Technical Problem

Existing poloxamers like Poloxamer 188 contribute significantly to foam generation in sparged bioreactors while providing shear protection, and alternative non-toxic, low-foaming options are needed for optimal cell viability and protein production in cell culture media.

Method used

The use of poloxamers with a polypropylene oxide block of 45% and ethylene oxide percentage between 75-90% (w/w) and molecular weight of 300-700 g/mol, which provide effective shear protection and reduce foam formation, allowing for reduced antifoam agent use.

Benefits of technology

These poloxamers maintain cell viability and productivity by minimizing foam and shear stress, enabling equal or improved performance with reduced antifoam agent usage compared to Poloxamer 188.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007824943000005
    Figure 0007824943000005
  • Figure 0007824943000006
    Figure 0007824943000006
  • Figure 0007824943000007
    Figure 0007824943000007
Patent Text Reader

Abstract

The present invention relates to the use of poloxamers as cell culture medium additives. Poloxamers are suitable for foam reduction and shear protection.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Poloxamer for cell culture The present invention relates to the use of poloxamers as cell culture medium additives. Poloxamers are suitable for foam reduction as well as for shear protection. [Background technology]

[0002] Background of the Invention Poloxamers (especially poloxamer 188) are used in many industrial applications, cosmetics, and pharmaceuticals. They are also used in cell culture media processes. Addition of poloxamers (especially poloxamer 188) to cell culture media significantly improves cell viability. High cell viability is important for optimal protein production. Why poloxamers improve cell viability is not fully understood. It is believed that poloxamers reduce shear stress and, in this way, protect cells from damage. Poloxamers are nonionic surfactants that can concentrate at the gas bubble / medium interface and prevent cell attachment to gas bubbles, thus protecting cells from damage if the bubbles burst. They may also reduce impact when the bubbles burst. Some publications claim that poloxamers improve the rate of oxygen transfer from the gas to the liquid phase, but others contradict these findings. There are also indications that poloxamers may "repair" small defects in cell membranes.

[0003] Unfortunately, poloxamer 188 significantly contributes to stabilizing the foam generated in sparged bioreactors. Therefore, non- or low-foaming alternatives to poloxamer 188 are desirable.

[0004] Poloxamers with a high propylene oxide / ethylene oxide ratio and therefore high hydrophobicity are known, as described by Schmolka IR (Schmolka, Journal of the American Oil Chemists' Society (1977), 54(3), 110-16). Poloxamers 101, 181, 182, and 184 are examples of such antifoaming poloxamers. However, poloxamer 181 was described by Murhammer (DW Murhammer, CF Gochee, Biotechnol. Prog. 1990, 6, 142-146) as being toxic to insect cells. Poloxamer 105 was described by Murhammer (see above) as generating fewer bubbles than poloxamer 188 and not inhibiting cell growth of insect cells. Murhammer hypothesized a correlation between reduced bubble formation and reduced polymer length. However, issues with toxicity also need to be considered: many poloxamers with average molecular weights around 2000, such as Poloxamer 105, are toxic to cells. Summary of the Invention

[0005] It has now been found that certain poloxamers, regardless of molecular weight, meet all requirements regarding toxicity, foam formation, and shear stress protection. The requirement for ideal compatibility in cell culture is a certain PPO (polypropylene oxide) block length combined with a defined percentage of PEO (polyethylene oxide) moieties. The molecular weight of the PPO block was found to correlate with maximum foam height. For poloxamers with an ethylene oxide percentage of >45%, the higher the molecular weight of the PPO block, the higher the maximum foam height. It has further been found that poloxamers with an ethylene oxide percentage of >45% (w / w) and a polypropylene oxide block of <700 g / mol are well suited as low-foaming alternatives to poloxamer 188 in cell culture because they also perform well as shear-stress protectants and are typically non-toxic.

[0006] The present invention therefore relates to a cell culture medium comprising a poloxamer with a polypropylene oxide block of <700 g / mol and a percentage of ethylene oxide of >45%. In a preferred embodiment, the molecular weight of the PPO block is 300 to 700 g / mol. In a preferred embodiment, the percentage of PEO is between 47 and 90%.

[0007] In a highly preferred embodiment, the percentage of polyethylene oxide is between 75 and 90% (w / w) and the molecular weight of the PPO block is between 300 and 700 g / mol.

[0008] Poloxamers with the described attributes may be liquid or solid, e.g., at room temperature; in a highly preferred embodiment, the poloxamers are solid at room temperature so that they can be milled and processed equivalently to other dry powder media components.

[0009] In a preferred embodiment, the cell culture medium comprises a poloxamer in an amount between 0.1 and 10 g / L, calculated for the liquid medium. In a highly preferred embodiment, the amount of poloxamer is between 0.5 and 2 g / L, calculated for the liquid medium. In one embodiment, the cell culture medium is a chemically defined medium. In one embodiment, the cell culture medium is a dry powder or a dry condensed medium.

[0010] In another embodiment, the cell culture medium comprises at least one or more sugar components, one or more amino acids, one or more vitamins or vitamin precursors, one or more salts, one or more buffer components, one or more cofactors, and one or more nucleic acid components.

[0011] The present invention also relates to a process for cell culture, whereby cells are cultivated in a liquid medium comprising a poloxamer with a polypropylene oxide block <700 g / mol and an ethylene oxide percentage >45%. Preferably, the process includes stirring and / or sparging. In a preferred embodiment, the molecular weight of the PPO block is 300 to 700 g / mol.

[0012] In a highly preferred embodiment, the percentage of ethylene oxide is between 75 and 90% (w / w) and the molecular weight of the PPO block is between 300 and 700 g / mol.

[0013] In a preferred embodiment, the amount of antifoam agent in the liquid medium is reduced compared to an otherwise identical cell culture medium but containing 188 poloxamer instead of a poloxamer with a polypropylene oxide block of <700 g / mol and an ethylene oxide percentage >45%.

[0014] The present invention also relates to a method for reducing bubble formation in stirred and / or sparged cell cultures, whereby cells are maintained at <700 g / mol. When cells are cultured in a liquid medium containing a poloxamer with a polypropylene oxide block and an ethylene oxide percentage of >45%, bubble formation is reduced compared to cells cultured under the same conditions in a cell culture medium containing poloxamer 188 instead of a poloxamer with a polypropylene oxide block of <700 g / mol and an ethylene oxide percentage of >45%. [Brief explanation of the drawings]

[0015] figure [Figure 1] Figures 1 and 2 show the results of the toxicity assay. Further details can be found in Example 1. [Figure 2] Figures 1 and 2 show the results of the toxicity assay. Further details can be found in Example 1. [Figure 3] Figure 3 shows the correlation between cell viability and %EO in poloxamers. Further details can be found in Example 1. [Figure 4] Figures 4 and 5 show the results of foam generation during continuous sparging. Further details can be found in Example 2. [Figure 5] Figures 4 and 5 show the results of foam generation during continuous sparging. Further details can be found in Example 2. [Figure 6] 6 shows the correlation between the average maximum bubble height and the average plateau height and the molecular weight of the polypropylene oxide block in the poloxamer. Further details can be found in Example 2. [Figure 7] Figure 7 shows the foam generation for various concentrations of Poloxamer 65. Further details can be found in Example 2. [Figure 8] Figure 8 shows the results of the shear stress assay. Further details can be found in Example 3. [Figure 9]Figure 9 shows the molecular weight distribution as determined by size exclusion chromatography (see Method 1) for Poloxamer 79. Mp indicates the peak molecular weight of a particular poloxamer. [Figure 10] Figure 10 shows the results of fed-batch cell culture. Further details can be found in Example 4. DETAILED DESCRIPTION OF THE INVENTION

[0016] definition Before describing the present invention in detail, it is to be understood that this invention is not limited to particular compositions or process steps, as such may vary.

[0017] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "poloxamer" includes plural poloxamers and the like. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The following terms are defined for the invention described herein:

[0018] The term "bioreactor," as used herein, refers to any manufactured or engineered device or system that supports a biologically active environment. In some examples, a bioreactor is a vessel or tank in which a cell culture process involving microorganisms or biochemically active substances derived from such microorganisms is carried out. Such processes may be aerobic or anaerobic. Commonly used bioreactors are typically cylindrical, range in size from liters to cubic meters, and are often made of stainless steel. In some embodiments described herein, the bioreactor may contain disposable components made of materials other than steel and is disposable. In some embodiments, it is a disposable bag in which a biologically active environment is maintained. It is contemplated that the total volume of the bioreactor may be anywhere from 100 mL up to 10,000 liters or more, depending on the particular process.

[0019] Agitated cell culture is cell culture achieved by agitating the cell culture medium with the cells in a bioreactor either permanently or one or more times during cell culture.

[0020] Agitation can be achieved by, for example, stirring, shaking, or shaking. In stirred tank bioreactors, one or more impellers may be provided, depending on the geometry of the vessel. The agitator type will be selected according to the primary mixing task and requirements of the process.

[0021] Sparged cell culture is cell culture in which gas is introduced into the bioreactor, typically by a sparger, also known as a bubbler or aerator.

[0022] Typically, in sparged cell culture, a mixture of air, oxygen, carbon dioxide, and nitrogen is introduced into the bioreactor through a sparger. Typical spargers for cell culture processes include drilled ring spargers, sintered microspargers, open-pipe spargers, and hybrid forms. Surface aeration also contributes to oxygen transfer, but the impact of surface aeration decreases during scale-up. The type of both agitator and sparger in mammalian cell culture processes will often be selected according to the shear sensitivity of the cells (Nienow, AW, 2006. Reactor engineering in large-scale animal cell culture, Cytotechnology, 50(1-3), p.9).

[0023] A cell culture medium according to the present invention is any mixture of components that maintains and / or supports in vitro cell growth and / or a specific physiological state, typically by providing at least one nutrient source to the cells. It may be a complex medium or a chemically defined medium. A cell culture medium can contain all components necessary to maintain and / or support in vitro cell growth, or only some components, so that additional components can be added separately. An example of a cell culture medium according to the present invention is a complete medium, which contains all components necessary to maintain and / or support in vitro cell growth, as well as a medium supplement or feed. In preferred embodiments, the cell culture medium is a complete medium, a perfusion medium, or a feed medium. A complete medium, typically referred to as a base medium, has a pH between 6.7 and 7.8. A feed medium preferably has a pH below 8.5. Typically, the cell culture medium according to the present invention is used to maintain and / or support cell growth in a bioreactor.

[0024] A feed or feed medium is a cell culture medium that is not the base medium that supports initial growth and production in a cell culture, but is a medium added at a later stage to prevent nutrient depletion and sustain the production phase. A feed medium can have a higher concentration of some components compared to the base culture medium. For example, some components (such as amino acids or carbohydrate-containing nutrients) may be present in a feed medium at about 5x, 6x, 7x, 8x, 9x, 10x, 12x, 14x, 16x, 20x, 30x, 50x, 100x, 200x, 400x, 600x, 800x, or even about 1000x the concentration of the base medium.

[0025] Mammalian cell culture media is a mixture of components that maintain and / or support the in vitro growth of mammalian cells. Examples of mammalian cells are human or animal cells, preferably CHO cells, COS cells, I Vero cells, BHK cells, AK-1 cells, SP2 / 0 cells, L5.1 cells, hybridoma cells, or human cells.

[0026] A chemically defined cell culture medium is a cell culture medium that does not contain any chemically undefined substances. This means that the chemical composition of all chemicals used in the medium is known. Chemically defined media do not contain any yeast, animal, or plant tissue; they do not contain feeder cells, serum, hydrolysates, extracts, or digests, or other poorly defined components. Chemically undefined or poorly defined chemical components are those whose chemical composition and structure are not known and exist in a variety of compositions or can only be defined through extensive experimental effort comparable to the evaluation of the chemical composition and structure of proteins like insulin, albumin, or casein.

[0027] Powdered cell culture media or dry powder media are cell culture media that typically result from a milling or freeze-drying process. This means that powdered cell culture media are granular, particulate media—not liquid media. The term "dry powder" may be used interchangeably with the term "powder;" however, as used herein, "dry powder" refers solely to the macroscopic appearance of the granulated material and is not intended to imply that the material is thoroughly mixed and free of agglomerated solvents, unless otherwise specified.

[0028] Dry granulated medium is a dry medium resulting from a wet or dry granulation process, e.g., spray drying, wet granulation, or dry compaction, and typically has a particle size greater than 0.5 mm, e.g., 0.5 to 5 mm. Dry compaction is typically performed using a roll press. US 6,383,810 B2 discloses a method for producing a wet granulated eukaryotic cell culture medium powder. The method includes wetting a dry powder cell culture medium with a solvent and then re-drying the wet medium to obtain a dry granulated cell culture medium. Preferably, the dry granulated medium is a medium resulting from roller compaction of a dry powder medium. As used herein, the term "dry" refers solely to the macroscopic appearance of the granulated material and, unless otherwise specified, is not intended to imply that the material is thoroughly mixed and free of agglomerated solvent.

[0029] For use in cell culture, i.e., to cultivate cells, liquid cell culture media are added to cells. Dry powder or dry compacted cell culture media are then dissolved in an appropriate amount of liquid, such as water or an aqueous buffer, to generate a liquid cell culture medium that can be contacted by cells. Because the composition of the liquid cell culture medium directly affects the cells, the concentration of the cell culture medium is often provided in weight per liter, such as mg per liter, to define the concentration of the component in the liquid medium to be added to the cells. The amount of the component in the dry powder or dry compacted medium needs to be adjusted so that when dissolved in a certain amount of liquid, the desired concentration of the component in the resulting liquid medium is achieved.

[0030] According to the present invention, the cells cultured by the medium may be prokaryotic cells, such as bacterial cells, or eukaryotic cells, such as plant or animal cells. The cells may be normal, immortalized, diseased, transformed, mutated, somatic, embryonic, stem, progenitor, or fetal cells, any of which may be an established or transformed cell line or obtained from a natural source. The average molecular weight according to the Pharmacopoeias is determined by titration using a phthalic anhydride-pyridine solution. The average molecular weight as determined by SEC is determined as follows: Weight average molecular weight: Mw=Σ i N i M i 2 / (Σ i N i M i ) Number average molecular weight: M n =Σ i N i M i / (Σ i N i ) Peak molecular weight: M p = maximum N i Molecular weight at N i = number of polymer species in fraction i M i = molecular weight of polymer species in fraction i SEC conditions: Calibration Standard: PEG (see Example (Method 1) for details) Eluent:THF Flow rate: 1ml / min Injection volume: 100μl Column: Particle size = 5 μm, Material = Styrene-divinylbenzene Temperature: 40℃

[0031] Cell culture media can be in the form of an aqueous liquid or a dry powder that is dissolved in water or an aqueous buffer for use. Those skilled in the art can select a suitable cell culture medium for a specific, envisioned purpose. Cell culture media according to the present invention, particularly complete media containing all the components necessary to maintain and / or support in vitro cell growth, typically contain at least one or more sugar components, one or more amino acids, one or more vitamins or vitamin precursors, one or more salts, one or more buffer components, one or more cofactors, and one or more nucleic acid components. They may additionally contain chemically defined biochemicals, such as recombinant proteins, e.g., r-insulin, r-BSA, r-transferrin, r-cytokines, etc.

[0032] The sugar moiety can be any mono- or disaccharide, such as glucose, galactose, ribose, or fructose (examples of monosaccharides), or sucrose, lactose, or maltose (examples of disaccharides).

[0033] Examples of amino acids according to the invention are tyrosine, the proteinogenic amino acids, in particular the essential amino acids leucine, isoleucine, lysine, methionine, phenylalanine, arginine, threonine, tryptophan and valine, as well as non-proteinogenic amino acids from the class of D-amino acids, whereby L-amino acids are preferred. The term amino acid further includes the salts of the amino acids, from the class of sodium salts, or the respective hydrates or hydrochlorides. For example, tyrosine means L- or D-tyrosine, preferably L-tyrosine, as well as salts or hydrates or hydrochlorides thereof.

[0034] Examples of vitamins are vitamin A (retinol, retinal, various retinoids, and four carotenoids), vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B3 (niacin, niacinamide), vitamin B5 (pantothenic acid), vitamin B6 (pyridoxine, pyridoxamine, pyridoxal), vitamin B7 (biotin), vitamin B9 (folic acid, folinic acid), vitamin B 12 Vitamins include: (cyanocobalamin, hydroxycobalamin, methylcobalamin), vitamin C (ascorbic acid), vitamin D (ergocalciferol, cholecalciferol), vitamin E (tocopherol, tocotrienol), and vitamin K (phylloquinone, menaquinone). Vitamin precursors are also included.

[0035] Examples of salts are inorganic ion-containing compounds such as bicarbonate, calcium, chloride, magnesium, phosphate, potassium, and sodium, or trace elements such as Co, Cu, F, Fe, Mn, Mo, Ni, Se, Si, Ni, Bi, V, and Zn. Examples are copper(II) sulfate pentahydrate (CuSO4.5H2O), sodium chloride (NaCl), calcium chloride (CaCl2.2H2O), potassium chloride (KCl), iron(II) sulfate, ammonium ferric citrate (FAC), anhydrous sodium dihydrogen phosphate (NaH2PO4), anhydrous magnesium sulfate (MgSO4), anhydrous sodium monohydrogen phosphate (Na2HPO4), magnesium chloride hexahydrate (MgCl26H2O), zinc sulfate heptahydrate. Examples of buffers are CO2 / HCO3 (carbonate), phosphate, HEPES, PIPES, ACES, BES, TES, MOPS, and TRIS.

[0036] Examples of cofactors are thiamine derivatives, biotin, vitamin C, NAD / NADP, cobalamin, flavin mononucleotide and derivatives, glutathione, heme nucleotide phosphate and derivatives.

[0037] Nucleic acid components according to the invention are nucleobases such as cytosine, guanine, adenine, thymine or uracil, nucleosides such as cytidine, uridine, adenosine, guanosine and thymidine, and nucleotides such as adenosine monophosphate or adenosine diphosphate or adenosine triphosphate.

[0038] Feed media may have different compositions compared to complete media. They typically contain amino acids, trace elements, and vitamins. They may also contain sugar components, but sometimes for production reasons, sugar components are added in a separate feed.

[0039] Many biopharmaceutical production platforms are based on fed-batch cell culture protocols. The goal is typically to develop high-titer cell culture processes to meet increasing market demand and reduce production costs. Besides the use of high-performance recombinant cell lines, improvements in cell culture media and process parameters are required to achieve maximum production capacity.

[0040] In the curing process, the base medium supports initial growth and production, and the feed medium protects against nutrient depletion and sustains the production phase. Media are selected to accommodate the different metabolic requirements during the various production phases. Process parameter settings—including feed strategies and control parameters—define the chemical and physical environment favorable for cell growth and protein production.

[0041] In the perfusion process, cells are retained in the bioreactor through a cell retention device, while cell culture medium is continuously added and removed from the bioreactor through a pump. The advantages of perfusion are the possibility of reaching very high cell densities (due to constant medium exchange) and the possibility of producing very fragile recombinant proteins, since the product can be removed from the bioreactor daily, thus shortening the exposure time of the recombinant protein to high temperatures and reducing the redox potential or released cellular enzymes.

[0042] Processes for perfusion cell culture typically involve culturing cells in a bioreactor system that includes a bioreactor with a medium inlet and a harvest outlet, thereby

[0043] i. continuously, or one or more times, preferably continuously, during the cell culture process, fresh cell culture medium is injected into the bioreactor via the medium inlet;

[0044] ii. Continuously or one or more times, preferably continuously, during the cell culture process, harvest is removed from the bioreactor via a harvest outlet. The harvest typically includes cells, the target product produced by the cells, and the liquid cell culture medium.

[0045] Poloxamers are amphiphilic polymers with two hydrophilic blocks and a central hydrophobic block. Poloxamers are polyethylene glycol (PEG) / polypropylene glycol (PPG) triblock copolymers, whereby one PPG block is flanked on both sides by PEG blocks. The polyethylene glycol (PEG) moiety is often also called the polyethylene oxide (PEO) moiety. The polypropylene glycol (PPG) moiety is often also called the polypropylene oxide (PPO) moiety.

[0046] Poloxamer (CAS No. 9003-11-6), typically used in cell culture applications, is referred to as Poloxamer 188 and has the general formula I, with x and z preferably independently being 75-85, and y preferably being 25-30.

[0047] [ka] The poloxamers of the present invention can be found in the region with x=z=3-72 and y=5-12.

[0048] Some poloxamers are commercially available (Pluronic® or Lutrol®, e.g., Pluronic® solutions, gels, or solids such as Pluronic® F-68).

[0049] Alternatively, poloxamers can be made from raw materials according to methods known in the art (see, eg, US Pat. Nos. 3,579,465 and 3,740,421).

[0050] Further information regarding poloxamers can be found in Hagers Handbuch der Pharmazeutischen Praxis, volume 9 "Stoffe PZ", 1994, pages 282 to 284. Table 1 below shows examples of poloxamers.

[0051] All listed poloxamers were characterized by determining their percentage of ethylene oxide (%EO) and molecular weight distribution. %EO was determined using 1H NMR. Molecular weight distribution was determined by size exclusion chromatography (see e.g., Method 1). The peak molecular weight (Mp) was used to characterize each polymer. The molecular weight of the PPO block (MW PPO) was calculated from Mp and %EO.

[0052] [Table 1]

[0053] Detailed Description of the Invention Essential to the present invention is the discovery that certain poloxamers exhibit improved properties for use in cell culture. They not only provide shear protection, like poloxamer 188, but also exhibit reduced foam formation. Suitable poloxamers are also non-toxic to the cells being cultured.

[0054] Poloxamer 188 is often added to cell culture media to protect against hydrodynamic stress caused by sparging and / or agitation. It reduces surface tension and typically increases bubble formation. Because cells tend to adhere to the surface of the bubbles, they are pulled to the surface by the bubbles, trapped in the bubble layer, and killed. It has now been found that, using various compositions and other poloxamers, the positive shear stress protection properties can be maintained, but in addition, bubble formation is reduced.

[0055] Consequently, the amount of an antifoam agent for reducing foam formation, such as antifoam C, can be reduced or even eliminated when using a cell culture medium according to the present invention. In a preferred embodiment, the medium according to the present invention contains less, preferably at least 25% (w / w) less, and most preferably less than half the amount of an antifoam agent, such as antifoam C, that would be used in an equivalent cell culture under the same conditions and in the same medium but without a poloxamer as defined herein other than Poloxamer 188. Examples of antifoaming agents are preferably agents comprising polydimethylsiloxane (PDMS) and optionally silica particles, such as, for example, Dow-Corning Q7-2587 (O / W emulsion of 30.4% PDMS, 1.2-2.1% SiO2 particles), also called dimethicone or simethicone, Antifoam C from Sigma Aldrich (O / W emulsion of 29.4% PDMS, 1.2-2-1% SiO2 particles), and Foam Away from Gibco (30% simethicone emulsion in water).

[0056] Poloxamers identified as particularly suitable are those with a polypropylene oxide block of <700 g / mol and preferably an ethylene oxide percentage of >45%, typically between 45% and 95%, preferably between 45% and 90%, and most preferably between 75 and 90% (all w / w). In a preferred embodiment, the molecular weight of the PPO block is 300 to 700 g / mol.

[0057] In a highly preferred embodiment, the percentage of ethylene oxide is between 75 and 90% (w / w) and the molecular weight of the PPO block is between 300 and 700 g / mol.

[0058] Those skilled in the art know how to use poloxamers as components in cell culture media. They are aware of the appropriate amounts and formats for use. Typically, poloxamers are applied to cell cultures as part of the cell culture media. However, they can also be applied separately.

[0059] Poloxamers are typically present in the form of solids, e.g., particles, or liquids, e.g., oils, or thick liquids such as pastes, or aqueous solutions. Preferably, they are present in the form of solid particles. If the particle size needs to be adjusted, they can optionally be milled before being added to the cell culture medium.

[0060] The present invention is a cell culture medium comprising a poloxamer with a polypropylene oxide block of <700 g / mol and an ethylene oxide percentage of >45%. In a preferred embodiment, the molecular weight of the PPO block is 300 to 700 g / mol.

[0061] In a highly preferred embodiment, the percentage of ethylene oxide is between 75 and 90% (w / w) and the molecular weight of the PPO block is between 300 and 700 g / mol.

[0062] In other preferred embodiments, the cell culture medium contains no antifoaming agent or a reduced amount of antifoaming agent, preferably less than 50% compared to a cell culture medium that does not contain a poloxamer of the invention other than poloxamer 188.

[0063] The concentration of poloxamer in the cell culture medium is preferably between 0.1 and 10 g / L calculated for the liquid medium. In a highly preferred embodiment, the amount of poloxamer is between 0.5 and 2 g / L calculated for the liquid medium. The poloxamer can be one type of poloxamer, as defined above, or a mixture of two or more poloxamers, as defined above.

[0064] Preferably, the cell culture medium is a dry powder or dry granulated medium or a liquid medium. In the case of a dry medium, the medium is dissolved with a suitable amount of water or an aqueous buffer before use. The cell culture medium of the present invention can be used for any type of cell culture, which is any setup in which cells are cultured.

[0065] Cell culture can be carried out in any vessel suitable for culturing cells, such as a petri dish, islet, bottle, tube, well, vessel, bag, flask, and / or tank. Preferably, it is carried out in a bioreactor. Typically, the vessel is sterilized before use. Culturing is typically carried out by incubation of cells in an aqueous cell culture medium under suitable conditions, such as suitable temperature, osmolality, aeration, agitation, etc., which limit contamination with adventitious microorganisms from the environment. Those skilled in the art are aware of suitable incubation conditions for supporting or maintaining cell growth / culture.

[0066] The present invention therefore also relates to a process for cell culture, whereby cells are cultivated in a liquid medium comprising a poloxamer with a polypropylene oxide block of <700 g / mol and a percentage of ethylene oxide of >45%. The cell culture can be any setup suitable for culturing cells. Preferably, it is a batch, perfusion, or perfusion cell culture. Preferably, the process for culturing cells comprises the following steps: a) Providing a bioreactor b) Mixing the cells to be cultured with a cell culture medium according to the invention. c) incubating the mixture of step b).

[0067] In one aspect, the process comprises the following steps: a) Providing a bioreactor b) mixing the cells to be cultured with the cell culture medium according to the invention c) Incubating the mixture of step b), whereby the cell culture medium, in this case the feed medium, is added to the bioreactor continuously for the entire time or once or several times within the cell incubation time of step c).

[0068] The feed medium may be a cell culture medium according to the invention, but it may also be a poloxamer-free feed medium. Preferably, it is poloxamer-free.

[0069] In one embodiment, the bioreactor is a perfusion bioreactor. A perfusion bioreactor is a bioreactor in which perfusion cell culture can be performed. It typically includes a sealed bioreactor vessel during cell culture, an agitator in the vessel, a line for introducing fresh medium, a harvest line for removing a harvest stream containing cells, liquid medium, and the target product from the bioreactor, and a cell retention device in the harvest line that retains the cells while the liquid portion of the harvest can be collected. A review of perfusion cell culture providing details on a preferred setup can be found in "Perfusion mammalian cell culture for recombinant protein manufacturing - A critical review," Jean-Marc Bielser et al., Biotechnology Advances 36 (2018) 1328-1340.

[0070] In the perfusion process, cells are retained in the bioreactor through a cell retention device, while cell culture medium is continuously added and removed from the bioreactor through a pump. The advantages of perfusion are the possibility of reaching very high cell densities (due to constant medium exchange) and producing very fragile recombinant proteins, since the product can be removed from the bioreactor daily, thus shortening the exposure time of the recombinant protein to high temperatures and reducing the redox potential or released cellular proteases.

[0071] In one embodiment, the process of the present invention involves culturing cells in a bioreactor system comprising a bioreactor with a medium inlet and a harvest outlet, thereby

[0072] i. continuously, or one or more times, preferably continuously, during the cell culture process, fresh cell culture medium according to the present invention is injected into the bioreactor via the medium inlet;

[0073] ii. Continuously or one or more times, preferably continuously, during the cell culture process, harvest is removed from the bioreactor via a harvest outlet. The harvest typically includes cells, the target product produced by the cells, and the liquid cell culture medium.

[0074] When using the cell culture medium according to the invention, the culture shows equal productivity and reduced foam formation compared to a cell culture carried out under the same conditions but with a medium containing poloxamer 188 instead of the poloxamer defined above.

[0075] The present invention therefore also relates to a method for reducing bubble formation in stirred and / or sparged cell cultures, whereby cells are cultured in a liquid medium comprising a poloxamer with a polypropylene oxide block of <700 g / mol and a percentage of ethylene oxide >45%, and bubble formation is reduced compared to cells cultured under the same conditions in a cell culture medium comprising poloxamer 188 instead of a poloxamer with a polypropylene oxide block of <700 g / mol and a percentage of ethylene oxide >45%.

[0076] The present invention also relates to a method for culturing cells in stirred and / or sparged cell cultures, whereby the cells are cultured in a liquid medium comprising a poloxamer with a polypropylene oxide block of <700 g / mol and a percentage of ethylene oxide >45%, and the amount of antifoam agent in the liquid medium is reduced compared to cells cultured under the same conditions in a cell culture medium comprising poloxamer 188 instead of the poloxamer with a polypropylene oxide block of <700 g / mol and a percentage of ethylene oxide >45%. Preferably, the amount of antifoam agent is reduced by at least 25%, preferably by at least 50%.

[0077] The entire disclosures of all applications, patents, and publications cited above and below, and the corresponding EP20203086.2 application filed October 21, 2020, are hereby incorporated by reference.

[0078] example Method 1 All size exclusion chromatography (sec) measurements are performed as follows: Calibration Standards: PEG (Mp: 430, 982, 1,960, 3,020, 6,690, 12,300, 26,100, and 44,000 g / mol) Eluent:THF Flow rate: 1mL / min Injection volume: 100μl Column: Particle size = 5 μm, Material = Styrene-divinylbenzene Temperature: 40℃ Detector: Refractive Index (RI)

[0079] Molecular weight distribution curves were calculated for all poloxamers, and Mp (peak maximum) values ​​were determined (Table 1). An exemplary distribution curve is shown in Figure 9, which shows the molecular weight distribution determined by size exclusion chromatography for poloxamer 79a. Mp indicates the peak molecular weight of a particular poloxamer.

[0080] Method 2: Measurement of bubble generation of poloxamer in water at 37°C Preparation of poloxamer solution in water A solution of the target poloxamer in MilliQ-water was prepared at the selected concentration and then stirred overnight or mixed via a roller mixer until completely dispersed. Solutions were prepared by weight. Air bubble measurement Foam generation was tested by using a Dynamic Foam Analyzer DFA 100 (Kruess GmbH). The following parameters were applied: Flow rate (air): 0.3L / min Temperature: 37℃ Liquid capacity: 15mL Measurement duration: 60 minutes Height illumination: 20% Minimum bubble area: 1200μm 2 Maximum bubble area: 35mm 2 Minimum histogram area: 0mm 2 Maximum histogram area: 1mm 2

[0081] The poloxamer solution was injected into the glass column of a Foam Analyzer DFA 100. The solution was heated to 37°C, as this is the temperature used in the bioreactor. Gas flow was initiated, and foam formation (foam height, liquid height, and foam structure) was recorded by the Foam Analyzer over a 60-minute time frame. When the foam reached a maximum column height of 210 mm, the gas flow automatically stopped to prevent overflow.

[0082] Method 3 Toxicity assay To determine the toxicity characteristics of poloxamers, the following cell culture toxicity assay was performed with two in-house cell lines—CHO-DG44 and CHOZN. Both cell lines were passaged to at least passage 5 before being tested in experiments. Cellvento® CHO-220comp. (1.03687 | Merck KGaA; Darmstadt, Germany), a chemically defined cell culture medium containing 2 g / L poloxamer 188, was used as the basal medium for the toxicity assay. For the CHO-DG44 cell line, the basal medium was supplemented with 8 mM L-glutamine (1.00286 | CAS 56-85-9 | Merck KGaA; Darmstadt, Germany). The basal medium was prepared according to the user's guide. Stock solutions of each poloxamer were prepared at a concentration of 4 g / L. The stock solutions were allowed to dissolve for at least 1 hour. Dilutions with a poloxamer concentration of 1 g / L were prepared from the basal medium and stock solution. The pH was adjusted to 7.0 ± 0.1 with 25% hydrochloric acid (1.00316 | Merck KGaA; Darmstadt, Germany) and 32% sodium hydroxide solution (1.05587 | CA1310-73-2 | Merck KGaA; Darmstadt, Germany). Osmolality was measured and adjusted to 335 ± 15 mOsmol / kg with sodium chloride (1.06400 | CAS7647-14-5 | Merck KGaA; Darmstadt, Germany). The medium was sterilized by filtration using 0.22 μm Stericup® and Steritop® Filter Units (Merck KGaA; Darmstadt, Germany).

[0083] The starting VCD for each experiment is 0.5 x 10 in a volume of 30 mL. 6 Therefore, the cell suspension (15 × 10 6A sufficient volume of the culture medium (containing 1000 cells) was transferred into a 50 mL TPP TubeSpin® bioreactor (TPP; Trasadingen, Switzerland) and centrifuged at 1,200 rpm for 5 minutes at 4°C. The supernatant was discarded, and the cell pellet was resuspended in 30 mL of special medium. The cells were cultured for 4 days at 37°C, 320 rpm, 5% CO2, and 80% humidity. VCD and viability were measured on days 0, 1, 2, 3, and 4. Triplicates were applied per condition. In Figures 1 and 2, viability results are given as the mean plus or minus the standard deviation. VCD results were reported on day 4 along with their standard deviation.

[0084] Method 4 Shear stress assay To investigate the protective properties of poloxamers at very high shear rates, the following shear stress assay was developed. The CHO-S cell line used for this assay was passaged to at least passage 5 and up to passage 25 before testing for shear protection. Cellvento CHO-220 comp. (1.03687 | Merck KGaA; Darmstadt, Germany) containing 2 g / L poloxamer 188 and supplemented with L-glutamine (1.00286 | CA56-85-9 | Merck KGaA; Darmstadt, Germany) was used as the passage medium and was prepared according to the user's guide. Cellvento CHO-220 (1.03797 | Merck KGaA; Darmstadt, Germany) without poloxamer 188 and supplemented with 6 mM L-glutamine (1.00286 | CA 56-85-9 | Merck KGaA; Darmstadt, Germany) was used as the basal medium. The basal medium was prepared according to the user's guide. Optimized poloxamer 188 EMPROVE® EXPERT (1.37097 | lot 48854497711 | CA9003-11-6 | Merck KGaA; Darmstadt, Germany) at a concentration of 1 g / L was used as a positive control. A mixture of P188 EMPROVE and P407 (16758 | Lot BCBV0465 | CA9003-11-6 | Sigma-Aldrich, St. Louis, USA) at a concentration of 1 g / L and a ratio of 99:1 (m%) was used as a negative control (NC). A 1 g / L stock solution of each poloxamer was prepared. After weighing and adding to the medium base, the stock solution and the control were allowed to dissolve for at least 1 hour. The pH was then adjusted to 7.0 ± 0.1 using 25% hydrochloric acid (1.00316 | Merck KGaA; Darmstadt, Germany) and 32% sodium hydroxide solution (1.05587 | CA1310-73-2 | Merck KGaA; Darmstadt, Germany).Osmolality was measured and, if necessary, adjusted to 335 ± 15 mOsmol / kg with sodium chloride (1.06400 | CA 7647-14-5 | Merck KGaA; Darmstadt, Germany). Finally, the medium was sterilized by filtration using 0.22 μm Stericup® and Steritop® Filter Units (Merck KGaA; Darmstadt, Germany).

[0085] A 250 mL baffled shake flask (Corning; New York, USA) containing a total volume of 50 mL was used as the test vessel to generate shear stress at a high shaking speed of 350 rpm. 46 mL of special medium was pre-filled into the baffled shake flask. Each experiment was performed in triplicate. The shear stress assay was performed using 1.5 × 10 6 We started with 100 live cells / mL of VCD. Therefore, we added 1000 cells to the cell suspension (75 × 10 6 The required volume of 1000 cells (containing 1000 live cells) was transferred into a 50 mL TPP TubeSpin® bioreactor (TPP; Trasadingen, Switzerland) and centrifuged at 1,200 rpm for 5 minutes at 4°C. The supernatant was discarded, and the cell pellet was resuspended in 4 mL of special medium and eventually added to 46 mL of special medium prefilled in a baffled shake flask. Samples were taken immediately at time t=0. VCD and viability were subsequently measured. The baffled shake flasks were incubated for 4 hours at 37°C, 5% CO2, and 350 rpm. VCD and viability were measured every hour of shaking for 4 hours.

[0086] Survival results are given as the mean plus or minus the standard deviation in Figure 8. Relative VCD (rVCD) results were calculated as the ratio of VCD end and VCD start and Gaussian error propagation.

[0087] Method 5 Fed-batch cell culture A fed-batch cell culture was performed to evaluate the protective ability of poloxamers during the culture. CHOK1SVD1 cells were used. The culture was carried out in a rotating tube (TPP, Art. No. 87050) with a final volume of 30 mL at 37°C and a rotation speed of 320 rpm.

[0088] Before the start of sulfurization, cells were cultivated in cell culture medium 4CHO (Merck KGaA, 103795) containing 2 g / L poloxamer 188. To this medium, HT-supplements 100x (sodium-hypoxanthine (10 mM) and thymidine (1.6 mM), Gibco®, Life technologies, Art. No. 11067-030) and L-methionine sulfoximine (Sigma Aldrich M5379) were added. On day 0 of sulfurization, cells were centrifuged at 2000 rpm for 5 minutes, then resuspended in 4CHO+HT without poloxamer 188 and pooled.

[0089] CHOK1SVD1 cells were cultured at 0.2 x 10 per mL. 6 Cells were seeded under various conditions (four replicates each). For each condition, cell culture medium 4CHO (Merck KGaA, 4.74000.9999) without poloxamer 188 was used, and the selected poloxamer was added to achieve a concentration of 1 g / L. The solution was stirred for at least 2 hours to allow complete dispersion. Cells were fed on days 3, 5, 7, and 10. Glucose concentrations were measured daily starting from D3. A continuous feed of 6 g / L glucose was maintained on demand during the entire fermentation process.

[0090] VCD and viability analysis by ViCell (Beckman Coulter) and IgG determination using Cedex (Bio HT Analyzer, Roche) were performed daily.

[0091]

number

[0092] Example 1. Toxicity The toxic effects on CHO cells were investigated for the poloxamers listed in Table 1. The toxicity cell assay is described in Method 3. Poloxamers with less than 45% EO were found to be toxic for both CHO DG44 and CHOZN cell lines (Figures 1 and 2). Their addition to cell cultures resulted in a significant decrease in cell viability. The data show that viability is clearly related to %EO. Poloxamers with %EO<45 resulted in low viability and are therefore toxic to CHO cells (Figure 3). In contrast, addition of poloxamers with %EO>45 resulted in viability>90%. These samples are therefore non-toxic.

[0093] Figure 1: Toxicity assay of poloxamers on the CHO-DG44 cell line. Poloxamers are reported by increasing percentage of EO from left to right. Poloxamers were tested at a concentration of 1 g / L (gray bar) for 4 days (replication n=3). A. VCD of CHO-DG44 on day 4. Black line indicates 0.5 x 10 6 B. Viability of CHO-DG44 at day 4.

[0094] Figure 2: Toxicity assay of poloxamers on the CHOZN cell line. Poloxamers are reported by increasing percentage of EO from left to right. Poloxamers were tested at a concentration of 1 g / L (gray bar) for 4 days (replication n=3). A. VCD of CHOZN on day 4. Black line indicates 0.5 x 10 6 B. Viability of CHOZN at day 4. Figure 3: Correlation between cell viability and %EO in poloxamers.

[0095] Example 2: Foaming The foaming behavior of all non-toxic poloxamers was investigated. The experimental setup is described in Method 2. The foaming behavior of poloxamer 188 at a concentration of 0.25 g / L (i.e., 250 ppm) in water is reported in Figure 4. Within 50 s, a maximum foam height of 210 mm (i.e., the length of the foam analyzer column) was reached and the measurement was automatically stopped by the instrument to prevent overflow.

[0096] Poloxamer 101 was chosen as a negative control, and as expected, only very small bubbles were created upon sparging (Figure 4), and the bubbles disappeared immediately after sparging stopped (data not shown). This behavior is in stark contrast to Poloxamer 188.

[0097] Poloxamer 105, due to its intermediate hydrophobicity (50% EO), was expected to generate more foam than Poloxamer 101 but less foam than Poloxamer 188. Surprisingly, the foaming behavior of Poloxamer 105 was found to be very similar to Poloxamer 188. The maximum foam height was reached after 44 seconds (Figure 4).

[0098] Foam generation during continuous sparging at 37°C for poloxamers 99, 129, 128, 108, 78, 138, and 126 shows similar foaming behavior as for poloxamers 188 and 105. After 44-50 seconds, a maximum foam height of 210 mm was reached and sparging ceased. Differences were only observed in bubble collapse, but bubble collapse is not considered relevant in the bioreactor because the process was carried out under continuous sparging.

[0099] For poloxamers 79a, 79b, 66, 65, 55, 46, and 37, foam heights between 190 and 60 mm were reached for a short period of time, but then the foam height quickly decreased, and it reached a stable height of about 30–70 mm (Figure 5, Table). The decrease in foam height and the formation of a stable foam level, i.e., a plateau height, can be explained in terms of an equilibrium between foam formation due to sparging and bubble collapse, due to drainage and bubble coalescence.

[0100] Figure 5: Foam generation during continuous sparging of poloxamers with various hydrophobicities and molecular weights (250 ppm aqueous solution) at 37°C. The plot shows maximum foam and plateau height. The reported curve is one measurement selected from the replicates as representative of the trend for each poloxamer.

[0101] Table 2: Maximum foam height and plateau height. 0.25 g / L (250 ppm) poloxamer solution in water, 37°C. [Table 2]

[0102] Contrary to what is known from the literature, it turns out that the PPO block length is an important parameter influencing the foaming behavior. The molecular weight of the PPO block correlates with the maximum foam height (Figures 5 and 6, Table 2). The higher the molecular weight of the PPO block, the higher the maximum foam height. Figure 6: Correlation between average maximum bubble height as well as average plateau height and molecular weight of the polypropylene oxide block in the poloxamer.

[0103] Low foaming was observed for all poloxamers with a PPO molecular weight <700 g / mol, while the %EO may vary between 45% and 95%, with little effect on foaming behavior in this range.

[0104] Higher poloxamer concentrations result in more foam generation. This phenomenon is illustrated in Figure 7 for Poloxamer 65. The foaming behavior of Poloxamer 65 was tested at four different concentrations: 250, 500, 1,000, and 2,000 ppm. The maximum foam height and plateau height increased with increasing poloxamer concentration. This evidence demonstrates the importance of comparing the foaming behavior of various poloxamers at the same concentration. For all the above measurements, a concentration of 250 ppm was chosen to allow for the observation of differences in foaming behavior using the Dynamic Foam Analyzer DFA 100 and to prevent column overflow. The foaming tendency observed at 250 ppm is comparable to that observed at higher concentrations. Figure 7: Foam generation of aqueous solutions of Poloxamer 65 at 37° C. Various concentrations were tested.

[0105] Example 3: Shear stress protection In a shear stress protection assay (see Method 4), all non-toxic and low-foaming poloxamers were tested and compared to the benchmark poloxamer 188 (Figure 8). All poloxamers, except for the negative control, provide sufficient shear stress protection for CHO cells, similar to poloxamer 188 (Figure 8A). Very good viability rates of ≥90% are observed for all tested poloxamers, except for the negative control (Figure 8B). Figure 8: Shear stress assay of poloxamers on the CHO-S cell line. Poloxamers are reported by increasing percentage of EO from left to right.

[0106] Poloxamers were tested at a concentration of 1 g / L for 4 hours (n=3 replicates). The positive control, 1 g / L poloxamer 188, is shown on the left (diagonal stripes, n=32). As negative controls (NC), P188 and P407 at a concentration of 1 g / L and a ratio of 99:1 (wt%) were used (vertical stripes, n=32). A. Relative VCD: The relative VCD of CHO-S was calculated as the ratio VCD final / VCD starting. The dotted line represents the relative inoculum VCD (t=0). B. Viability (%) of CHO-S after 4 hours.

[0107] Example 4: Fed-batch cell culture Fed-batch cell cultures (see Method 5) were performed to investigate the shear stress protective properties of three different poloxamers, namely 75, 69, and 49, compared to the benchmark 188.

[0108] These poloxamers, like other poloxamers of the same molecular weight and degree of ethoxylation, are low-foaming and non-toxic. Poloxamer 75 is liquid and has an ethoxylation degree of 53.6; instead, poloxamers 69 and 49 are solid and more hydrophilic, with %EOs of around 88%. Poloxamer 49 also has a lower molecular weight compared to other poloxamers with comparable hydrophilicity. The solid, low-foaming poloxamers 69 and 49 are particularly attractive for implementation in cell culture media. Viable cell density, viability, and IgG productivity (Figure 10) are similar across all four conditions. The three custom-made poloxamers have comparable performance to poloxamer 188 and are fully confirmed as shear stress protectants supporting cell culture and antibody production.

[0109] Figure 10. Results of fed-batch cell culture. Cultures were carried out in roller tubes for 13 days. All poloxamer solutions in CHO cell culture medium had a concentration of 1 g / L. A. Viable cell density (VCD) of CHOK1SVD1 cells during fed-batch culture. Each value is the mean of four replicates for each condition. Error bars are the standard deviation of the mean. B. Viability (VCD) of CHOK1SVD1 cells during fed-batch culture. Each value is the mean of four replicates for each condition. Error bars are the standard deviation of the mean. C. Viability (VCD) of CHOK1SVD1 cells during fed-batch culture. Each value is the mean of four replicates for each condition. Error bars are the standard deviation of the mean.

Claims

1. A cell culture medium comprising a poloxamer with a polypropylene oxide block of <700 g / mol and a percentage of ethylene oxide of >45% (w / w).

2. 2. The cell culture medium according to claim 1, wherein the molecular weight of the PPO block is between 300 and 700 g / mol.

3. 3. The cell culture medium according to claim 1, wherein the percentage of ethylene oxide is between 75% and 90% (w / w) and the molecular weight of the PPO block is between 300 and 700 g / mol.

4. 4. The cell culture medium according to claim 1, comprising poloxamer in an amount of between 0.1 and 10 g / L calculated on the liquid medium.

5. The cell culture medium according to any one of claims 1 to 4, characterized in that it is a chemically defined medium.

6. 6. The cell culture medium according to claim 1, wherein the cell culture medium is a dry powder or a dry granulated medium.

7. 7. The cell culture medium of claim 1, comprising at least one or more sugar components, one or more amino acids, one or more vitamins or vitamin precursors, one or more salts, one or more buffer components, one or more cofactors, and one or more nucleic acid components.

8. 1. A process for cell culture, whereby cells are cultured in a liquid medium comprising a poloxamer with a polypropylene oxide block of <700 g / mol and a percentage of ethylene oxide of >45% (w / w).

9. 9. A process for cell culture according to claim 8, characterized in that the molecular weight of the PPO block is between 300 and 700 g / mol.

10. 10. A process for cell culture according to claim 8 or claim 9, characterized in that the percentage of ethylene oxide is between 75% and 90% (w / w) and the molecular weight of the PPO block is between 300 and 700 g / mol.

11. A process for cell culture according to any one of claims 8 to 10, characterized in that it comprises: a) Providing a bioreactor b) mixing cells to be cultured with the cell culture medium according to any one of claims 1 to 7; c) incubating the mixture of step b).

12. 12. Process for cell culture according to any one of claims 8 to 11, characterized in that the bioreactor is a perfusion bioreactor.

13. A process for cell culture according to any one of claims 8 to 11, characterized in that it comprises the following steps: a) Providing a bioreactor b) mixing cells to be cultured with the cell culture medium according to any one of claims 1 to 7; c) Incubating the mixture of step b), whereby the cell culture medium, in this case the feed medium, is added to the bioreactor either for the entire time or continuously once or several times within the cell incubation time of step c).

14. 13. The process for cell culture according to any one of claims 8 to 12, wherein the amount of antifoam agent in the liquid medium is reduced compared to an otherwise identical cell culture medium but comprising poloxamer 188 instead of a poloxamer with a polypropylene oxide block of <700 g / mol and a percentage of ethylene oxide >45% (w / w).

15. 1. A method for reducing bubble formation in stirred and / or sparged cell cultures, whereby cells are cultured in a liquid medium comprising a poloxamer with a polypropylene oxide block of <700 g / mol and a percentage of ethylene oxide >45% (w / w), and bubble formation is reduced compared to cells cultured under the same conditions in a cell culture medium comprising poloxamer 188 instead of a poloxamer with a polypropylene oxide block of <700 g / mol and a percentage of ethylene oxide >45% (w / w).

Citation Information

Patent Citations

  • Methods of evaluating cell culture additives

    US20160131634A1

  • Poloxamer compositions and methods of making and using same

    WO2019125783A1